{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:50:58Z","timestamp":1790884258529,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 104-2320-B-218-002-MY3-03"],"award-info":[{"award-number":["MOST 104-2320-B-218-002-MY3-03"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis B virus (HBV) infection is a major risk factor for the development of hepatocellular carcinoma (HCC), a leading cause of cancer mortality worldwide. Hepatitis B X protein (HBx) and pre-S2 mutant have been proposed as the two most important HBV oncoproteins that play key roles in HCC pathogenesis. Curcumin is a botanical constituent displaying potent anti-inflammatory and anti-cancer properties without toxic side effects. Phytosomal formulation of curcumin has been shown to exhibit enhanced bioavailability, improved pharmacokinetics, and excellent efficacy against many human diseases. However, effectiveness of phytosomal curcumin for HCC treatment remains to be clarified. In this study, we evaluated chemopreventive effect of phytosomal curcumin on HBV-related HCC by using a transgenic mouse model specifically expressing both HBx and pre-S2 mutant in liver. Compared with unformulated curcumin, phytosomal curcumin exhibited significantly greater effects on suppression of HCC formation, improvement of liver histopathology, decrease of lipid accumulation and leukocyte infiltration, and reduction of total tumor volume in transgenic mice. Moreover, phytosomal curcumin exerted considerably stronger effects on activation of anti-inflammatory PPAR\u03b3 as well as inhibition of pro-inflammatory NF-\u03baB than unformulated curcumin. Furthermore, phytosomal curcumin showed a comparable effect on suppression of oncogenic mTOR activation to unformulated curcumin. Our data demonstrated that phytosomal curcumin has promise for HCC chemoprevention in patients with chronic HBV infection.<\/jats:p>","DOI":"10.1038\/s41598-019-46891-5","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T10:02:58Z","timestamp":1563357778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Chemopreventive Effect of Phytosomal Curcumin on Hepatitis B Virus-Related Hepatocellular Carcinoma in A Transgenic Mouse Model"],"prefix":"10.1038","volume":"9","author":[{"given":"Chiao-Fang","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chuan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4588-2268","authenticated-orcid":false,"given":"Long-Bin","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ih-Jen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"key":"46891_CR1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245\u20131255 (2012).","journal-title":"Lancet"},{"issue":"Suppl 4","key":"46891_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","volume":"15","author":"AP Venook","year":"2010","unstructured":"Venook, A. P., Papandreou, C., Furuse, J. & de Guevara, L. L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15(Suppl 4), 5\u201313 (2010).","journal-title":"Oncologist"},{"key":"46891_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7603\/s40681-016-0016-2","volume":"6","author":"KC Cheng","year":"2016","unstructured":"Cheng, K. C. et al. Association of different types of liver disease with demographic and clinical factors. Biomedicine (Taipei) 6, 16 (2016).","journal-title":"Biomedicine (Taipei)"},{"key":"46891_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bpg.2014.08.007","volume":"28","author":"C Bosetti","year":"2014","unstructured":"Bosetti, C., Turati, F. & La Vecchia, C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 28, 753\u2013770 (2014).","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"46891_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-2008-1040651","volume":"4","author":"RP Beasley","year":"1984","unstructured":"Beasley, R. P. & Hwang, L. Y. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 4, 113\u2013121 (1984).","journal-title":"Semin Liver Dis"},{"key":"46891_CR6","doi-asserted-by":"crossref","unstructured":"Mani, S. K. K. & Andrisani, O. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells. Genes (Basel) 9 (2018).","DOI":"10.3390\/genes9030137"},{"key":"46891_CR7","doi-asserted-by":"publisher","first-page":"11630","DOI":"10.3748\/wjg.v20.i33.11630","volume":"20","author":"M Tarocchi","year":"2014","unstructured":"Tarocchi, M., Polvani, S., Marroncini, G. & Galli, A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol 20, 11630\u201311640 (2014).","journal-title":"World J Gastroenterol"},{"key":"46891_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1365-2036.2011.04990.x","volume":"35","author":"AK Singal","year":"2012","unstructured":"Singal, A. K. & Fontana, R. J. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 35, 674\u2013689 (2012).","journal-title":"Aliment Pharmacol Ther"},{"key":"46891_CR9","doi-asserted-by":"publisher","first-page":"e98865","DOI":"10.1371\/journal.pone.0098865","volume":"9","author":"W Ke","year":"2014","unstructured":"Ke, W. et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One 9, e98865 (2014).","journal-title":"PLoS One"},{"key":"46891_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJM198110293051807","volume":"305","author":"DA Shafritz","year":"1981","unstructured":"Shafritz, D. A., Shouval, D., Sherman, H. I., Hadziyannis, S. J. & Kew, M. C. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 305, 1067\u20131073 (1981).","journal-title":"N Engl J Med"},{"key":"46891_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ng.2295","volume":"44","author":"WK Sung","year":"2012","unstructured":"Sung, W. K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44, 765\u2013769 (2012).","journal-title":"Nat Genet"},{"key":"46891_CR12","doi-asserted-by":"crossref","first-page":"27724","DOI":"10.18632\/oncotarget.8388","volume":"7","author":"HW Tsai","year":"2016","unstructured":"Tsai, H. W. et al. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma. Oncotarget 7, 27724\u201327734 (2016).","journal-title":"Oncotarget"},{"key":"46891_CR13","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.3748\/wjg.v21.i27.8249","volume":"21","author":"S Kubo","year":"2015","unstructured":"Kubo, S. et al. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 21, 8249\u20138255 (2015).","journal-title":"World J Gastroenterol"},{"key":"46891_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.21037\/jgo.2017.03.14","volume":"8","author":"PJ Zamor","year":"2017","unstructured":"Zamor, P. J., deLemos, A. S. & Russo, M. W. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 8, 229\u2013242 (2017).","journal-title":"J Gastrointest Oncol"},{"key":"46891_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1478-3231.2007.01652.x","volume":"28","author":"A Tan","year":"2008","unstructured":"Tan, A., Yeh, S. H., Liu, C. J., Cheung, C. & Chen, P. J. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 28, 175\u2013188 (2008).","journal-title":"Liver Int"},{"key":"46891_CR16","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","volume":"64","author":"M Levrero","year":"2016","unstructured":"Levrero, M. & Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 64, S84\u2013S101 (2016).","journal-title":"J Hepatol"},{"key":"46891_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1517\/14728222.2014.867947","volume":"18","author":"MA Feitelson","year":"2014","unstructured":"Feitelson, M. A., Bonamassa, B. & Arzumanyan, A. The roles of hepatitis B virus-encoded X protein in virus replication and the pathogenesis of chronic liver disease. Expert Opin Ther Targets 18, 293\u2013306 (2014).","journal-title":"Expert Opin Ther Targets"},{"key":"46891_CR18","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.3748\/wjg.v21.i38.10732","volume":"21","author":"M Geng","year":"2015","unstructured":"Geng, M., Xin, X., Bi, L. Q., Zhou, L. T. & Liu, X. H. Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis. World J Gastroenterol 21, 10732\u201310738 (2015).","journal-title":"World J Gastroenterol"},{"key":"46891_CR19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/j.1440-1746.2008.05348.x","volume":"23","author":"IJ Su","year":"2008","unstructured":"Su, I. J., Wang, H. C., Wu, H. C. & Huang, W. Y. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J Gastroenterol Hepatol 23, 1169\u20131174 (2008).","journal-title":"J Gastroenterol Hepatol"},{"key":"46891_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3727\/096368916X694382","volume":"26","author":"CF Teng","year":"2017","unstructured":"Teng, C. F., Wu, H. C., Shyu, W. C., Jeng, L. B. & Su, I. J. Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cell Transplant 26, 429\u2013438 (2017).","journal-title":"Cell Transplant"},{"key":"46891_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3934\/medsci.2018.2.90","volume":"5","author":"HY Chang","year":"2018","unstructured":"Chang, H. Y. et al. Ground glass hepatocytes provide targets for therapy or prevention of hepatitis B virus-related hepatocellular carcinoma. AIMS Med Sci 5, 90\u2013101 (2018).","journal-title":"AIMS Med Sci"},{"key":"46891_CR22","doi-asserted-by":"crossref","unstructured":"Li, T. N. et al. Intrahepatic HBV large surface antigen induces hepatocyte hyperploidy via failure of cytokinesis. J Pathol (2018).","DOI":"10.1002\/path.5102"},{"key":"46891_CR23","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.humpath.2013.10.039","volume":"45","author":"HC Wu","year":"2014","unstructured":"Wu, H. C. et al. Ground-glass hepatocytes co-expressing hepatitis B virus X protein and surface antigens exhibit enhanced oncogenic effects and tumorigenesis. Hum Pathol 45, 1294\u20131301 (2014).","journal-title":"Hum Pathol"},{"key":"46891_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2016.08.006","volume":"40\u201341","author":"A Bishayee","year":"2016","unstructured":"Bishayee, A. & Sethi, G. Bioactive natural products in cancer prevention and therapy: Progress and promise. Semin Cancer Biol 40\u201341, 1\u20133 (2016).","journal-title":"Semin Cancer Biol"},{"key":"46891_CR25","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/1750-3841.13793","volume":"82","author":"A Shehzad","year":"2017","unstructured":"Shehzad, A., Qureshi, M., Anwar, M. N. & Lee, Y. S. Multifunctional Curcumin Mediate Multitherapeutic Effects. J Food Sci 82, 2006\u20132015 (2017).","journal-title":"J Food Sci"},{"key":"46891_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tips.2008.11.002","volume":"30","author":"BB Aggarwal","year":"2009","unstructured":"Aggarwal, B. B. & Sung, B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30, 85\u201394 (2009).","journal-title":"Trends Pharmacol Sci"},{"key":"46891_CR27","doi-asserted-by":"publisher","first-page":"89369","DOI":"10.1155\/2007\/89369","volume":"2007","author":"A Jacob","year":"2007","unstructured":"Jacob, A., Wu, R., Zhou, M. & Wang, P. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation. PPAR Res 2007, 89369 (2007).","journal-title":"PPAR Res"},{"key":"46891_CR28","doi-asserted-by":"publisher","first-page":"981963","DOI":"10.1155\/2009\/981963","volume":"2009","author":"S Samuhasaneeto","year":"2009","unstructured":"Samuhasaneeto, S., Thong-Ngam, D., Kulaputana, O., Suyasunanont, D. & Klaikeaw, N. Curcumin decreased oxidative stress, inhibited NF-kappaB activation, and improved liver pathology in ethanol-induced liver injury in rats. J Biomed Biotechnol 2009, 981963 (2009).","journal-title":"J Biomed Biotechnol"},{"key":"46891_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ijc.21932","volume":"119","author":"CS Beevers","year":"2006","unstructured":"Beevers, C. S., Li, F., Liu, L. & Huang, S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 119, 757\u2013764 (2006).","journal-title":"Int J Cancer"},{"key":"46891_CR30","first-page":"4821","volume":"15","author":"Z Pan","year":"2018","unstructured":"Pan, Z. et al. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression. Oncol Lett 15, 4821\u20134826 (2018).","journal-title":"Oncol Lett"},{"key":"46891_CR31","doi-asserted-by":"crossref","first-page":"108498","DOI":"10.18632\/oncotarget.22590","volume":"8","author":"MT Cao","year":"2017","unstructured":"Cao, M. T. et al. Curcumin downregulates the expression of Snail via suppressing Smad2 pathway to inhibit TGF-beta1-induced epithelial-mesenchymal transitions in hepatoma cells. Oncotarget 8, 108498\u2013108508 (2017).","journal-title":"Oncotarget"},{"key":"46891_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.intimp.2017.01.016","volume":"44","author":"R Afrin","year":"2017","unstructured":"Afrin, R. et al. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-kappaB translocation. Int Immunopharmacol 44, 174\u2013182 (2017).","journal-title":"Int Immunopharmacol"},{"key":"46891_CR33","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s13277-014-2778-z","volume":"36","author":"MM Abouzied","year":"2015","unstructured":"Abouzied, M. M. et al. Curcumin ameliorate DENA-induced HCC via modulating TGF-beta, AKT, and caspase-3 expression in experimental rat model. Tumour Biol 36, 1763\u20131771 (2015).","journal-title":"Tumour Biol"},{"key":"46891_CR34","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3892\/ijo.2013.2107","volume":"43","author":"MX Xu","year":"2013","unstructured":"Xu, M. X. et al. Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the wnt signaling pathway. Int J Oncol 43, 1951\u20131959 (2013).","journal-title":"Int J Oncol"},{"key":"46891_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/138920112798868791","volume":"13","author":"AS Darvesh","year":"2012","unstructured":"Darvesh, A. S., Aggarwal, B. B. & Bishayee, A. Curcumin and liver cancer: a review. Curr Pharm Biotechnol 13, 218\u2013228 (2012).","journal-title":"Curr Pharm Biotechnol"},{"key":"46891_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","volume":"4","author":"P Anand","year":"2007","unstructured":"Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol Pharm 4, 807\u2013818 (2007).","journal-title":"Mol Pharm"},{"key":"46891_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1208\/s12248-016-0003-2","volume":"19","author":"RI Mahran","year":"2017","unstructured":"Mahran, R. I., Hagras, M. M., Sun, D. & Brenner, D. E. Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy. AAPS J 19, 54\u201381 (2017).","journal-title":"AAPS J"},{"key":"46891_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.2174\/0929867323666161028160855","volume":"24","author":"D Matias","year":"2017","unstructured":"Matias, D., Rijo, P. & Reis, C. P. Phytosomes as Biocompatible Carriers of Natural Drugs. Curr Med Chem 24, 568\u2013589 (2017).","journal-title":"Curr Med Chem"},{"key":"46891_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.biopha.2016.11.098","volume":"85","author":"H Mirzaei","year":"2017","unstructured":"Mirzaei, H. et al. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother 85, 102\u2013112 (2017).","journal-title":"Biomed Pharmacother"},{"key":"46891_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1021\/np1007262","volume":"74","author":"J Cuomo","year":"2011","unstructured":"Cuomo, J. et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74, 664\u2013669 (2011).","journal-title":"J Nat Prod"},{"key":"46891_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00280-006-0355-x","volume":"60","author":"TH Marczylo","year":"2007","unstructured":"Marczylo, T. H. et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60, 171\u2013177 (2007).","journal-title":"Cancer Chemother Pharmacol"},{"key":"46891_CR42","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.bbrc.2005.12.089","volume":"340","author":"BK Wu","year":"2006","unstructured":"Wu, B. K. et al. Blocking of G1\/S transition and cell death in the regenerating liver of Hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 340, 916\u2013928 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"46891_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/path.4850","volume":"241","author":"YC Teng","year":"2017","unstructured":"Teng, Y. C. et al. Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice. J Pathol 241, 463\u2013474 (2017).","journal-title":"J Pathol"},{"key":"46891_CR44","doi-asserted-by":"publisher","first-page":"10508","DOI":"10.1073\/pnas.1000788107","volume":"107","author":"M Kawai","year":"2010","unstructured":"Kawai, M. et al. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci USA 107, 10508\u201310513 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"46891_CR45","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0002-9440(10)63599-7","volume":"163","author":"HC Wang","year":"2003","unstructured":"Wang, H. C. et al. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol 163, 2441\u20132449 (2003).","journal-title":"Am J Pathol"},{"key":"46891_CR46","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/carcin\/bgh207","volume":"25","author":"YH Hsieh","year":"2004","unstructured":"Hsieh, Y. H. et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 25, 2023\u20132032 (2004).","journal-title":"Carcinogenesis"},{"key":"46891_CR47","doi-asserted-by":"publisher","first-page":"46384","DOI":"10.1074\/jbc.M403568200","volume":"279","author":"JH Hung","year":"2004","unstructured":"Hung, J. H. et al. Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem 279, 46384\u201346392 (2004).","journal-title":"J Biol Chem"},{"key":"46891_CR48","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/hep.22889","volume":"49","author":"JC Yang","year":"2009","unstructured":"Yang, J. C. et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 49, 1962\u20131971 (2009).","journal-title":"Hepatology"},{"key":"46891_CR49","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5483\/BMBRep.2008.41.2.158","volume":"41","author":"SY Kim","year":"2008","unstructured":"Kim, S. Y. et al. Hepatitis B virus X protein enhances NFkappaB activity through cooperating with VBP1. BMB Rep 41, 158\u2013163 (2008).","journal-title":"BMB Rep"},{"key":"46891_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.febslet.2009.11.091","volume":"584","author":"HR Kim","year":"2010","unstructured":"Kim, H. R., Lee, S. H. & Jung, G. The hepatitis B viral X protein activates NF-kappaB signaling pathway through the up-regulation of TBK1. FEBS Lett 584, 525\u2013530 (2010).","journal-title":"FEBS Lett"},{"key":"46891_CR51","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00705-011-1099-4","volume":"156","author":"BY Jiao","year":"2011","unstructured":"Jiao, B. Y., Lin, W. S., She, F. F., Chen, W. N. & Lin, X. Hepatitis B virus X protein enhances activation of nuclear factor kappaB through interaction with valosin-containing protein. Arch Virol 156, 2015\u20132021 (2011).","journal-title":"Arch Virol"},{"key":"46891_CR52","doi-asserted-by":"publisher","first-page":"e41931","DOI":"10.1371\/journal.pone.0041931","volume":"7","author":"CJ Yen","year":"2012","unstructured":"Yen, C. J. et al. Hepatitis B virus X protein upregulates mTOR signaling through IKKbeta to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One 7, e41931 (2012).","journal-title":"PLoS One"},{"key":"46891_CR53","first-page":"735672","volume":"2014","author":"Z Wang","year":"2014","unstructured":"Wang, Z., Jin, W., Jin, H. & Wang, X. mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. Biomed Res Int 2014, 735672 (2014).","journal-title":"Biomed Res Int"},{"key":"46891_CR54","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1128\/JVI.02363-14","volume":"89","author":"CF Teng","year":"2015","unstructured":"Teng, C. F., Wu, H. C., Hsieh, W. C., Tsai, H. W. & Su, I. J. Activation of ATP citrate lyase by mTOR signal induces disturbed lipid metabolism in hepatitis B virus pre-S2 mutant tumorigenesis. J Virol 89, 605\u2013614 (2015).","journal-title":"J Virol"},{"key":"46891_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mc.22266","volume":"55","author":"CF Teng","year":"2016","unstructured":"Teng, C. F. et al. A biphasic response pattern of lipid metabolomics in the stage progression of hepatitis B virus X tumorigenesis. Mol Carcinog 55, 105\u2013114 (2016).","journal-title":"Mol Carcinog"},{"key":"46891_CR56","doi-asserted-by":"publisher","first-page":"e0122373","DOI":"10.1371\/journal.pone.0122373","volume":"10","author":"CF Teng","year":"2015","unstructured":"Teng, C. F. et al. Hepatitis B Virus Pre-S2 Mutant Induces Aerobic Glycolysis through Mammalian Target of Rapamycin Signal Cascade. PLoS One 10, e0122373 (2015).","journal-title":"PLoS One"},{"key":"46891_CR57","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12272-015-0559-x","volume":"38","author":"JH Kim","year":"2015","unstructured":"Kim, J. H., Song, J. & Park, K. W. The multifaceted factor peroxisome proliferator-activated receptor gamma (PPARgamma) in metabolism, immunity, and cancer. Arch Pharm Res 38, 302\u2013312 (2015).","journal-title":"Arch Pharm Res"},{"key":"46891_CR58","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1182\/blood-2006-07-038026","volume":"110","author":"LH Wang","year":"2007","unstructured":"Wang, L. H., Yang, X. Y., Zhang, X. & Farrar, W. L. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C\/EBP. Blood 110, 4373\u20134384 (2007).","journal-title":"Blood"},{"key":"46891_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1172\/JCI7145","volume":"104","author":"CG Su","year":"1999","unstructured":"Su, C. G. et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104, 383\u2013389 (1999).","journal-title":"J Clin Invest"},{"key":"46891_CR60","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00018-008-7452-4","volume":"65","author":"H Hatcher","year":"2008","unstructured":"Hatcher, H., Planalp, R., Cho, J., Torti, F. M. & Torti, S. V. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65, 1631\u20131652 (2008).","journal-title":"Cell Mol Life Sci"},{"key":"46891_CR61","first-page":"3185","volume":"29","author":"SM Johnson","year":"2009","unstructured":"Johnson, S. M. et al. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt\/mTOR signaling. Anticancer Res 29, 3185\u20133190 (2009).","journal-title":"Anticancer Res"},{"key":"46891_CR62","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/hep.24529","volume":"54","author":"CF Teng","year":"2011","unstructured":"Teng, C. F. et al. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 54, 1199\u20131207 (2011).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46891-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46891-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46891-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:33:03Z","timestamp":1671276783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46891-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46891"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46891-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"11 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10338"}}